Does vitamin D receptor and calcium receptor activation therapy play a role in the histopathologic alterations of parathyroid glands in refractory uremic hyperparathyroidism?

Clin J Am Soc Nephrol. 2008 May;3(3):794-9. doi: 10.2215/CJN.04150907. Epub 2008 Mar 5.

Abstract

Background and objectives: Vitamin D receptor activation by vitamin D sterols and calcium-sensing receptor stimulation by cinacalcet are the most powerful treatments of secondary hyperparathyroidism. This study was aimed to assess a possible association between histopathologic changes of parathyroid tissue and treatment modality.

Design, setting, participants, & measurements: Studies were performed on 82 parathyroids of 22 adult white hemodialysis patients undergoing first parathyroidectomy. The type of hyperplasia and the distribution of chief and oxyphil cells, expressed as oxyphil/chief cell ratio, were assessed. Three groups could be studied according to treatment modality: group A consisted of 6 patients who were treated with cinacalcet, intravenous calcitriol, and phosphate binders; group B consisted of 6 patients who were treated with intravenous calcitriol and phosphate binders, and group C consisted of 10 patients who were treated with phosphate binders alone.

Results: Sixty-eight (82.9%) out of 82 glands removed showed nodular hyperplasia. It was more frequent in groups A and B than in group C. A stepwise forward logistic regression model showed that the probability of nodular hyperplasia was higher in patients who were on calcitriol and/or cinacalcet therapy, in female gender and in patients with a higher body mass index. Oxyphil/chief cell ratio also was significantly different among the three groups. Cinacalcet treatment was the only predictor of this ratio.

Conclusions: An association was found between calcitriol and/or cinacalcet therapy and a high prevalence of nodular hyperplasia, and between cinacalcet therapy and high oxyphil/chief cell ratio. The meaning of the observed associations remains uncertain.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Aged
  • Body Mass Index
  • Calcitriol / adverse effects
  • Calcitriol / therapeutic use*
  • Cinacalcet
  • Drug Therapy, Combination
  • Female
  • Humans
  • Hyperparathyroidism, Secondary / drug therapy*
  • Hyperparathyroidism, Secondary / etiology
  • Hyperparathyroidism, Secondary / pathology
  • Hyperparathyroidism, Secondary / surgery
  • Hyperplasia
  • Logistic Models
  • Male
  • Middle Aged
  • Naphthalenes / adverse effects
  • Naphthalenes / therapeutic use*
  • Oxyphil Cells / drug effects
  • Oxyphil Cells / pathology
  • Parathyroid Glands / drug effects*
  • Parathyroid Glands / pathology
  • Parathyroid Glands / surgery
  • Parathyroidectomy
  • Phosphates / therapeutic use
  • Receptors, Calcitriol / agonists*
  • Receptors, Calcium-Sensing / agonists*
  • Renal Dialysis
  • Risk Assessment
  • Risk Factors
  • Sex Factors
  • Treatment Failure
  • Uremia / complications*
  • Uremia / drug therapy
  • Uremia / pathology
  • Uremia / surgery
  • Vitamins / adverse effects
  • Vitamins / therapeutic use*

Substances

  • Naphthalenes
  • Phosphates
  • Receptors, Calcitriol
  • Receptors, Calcium-Sensing
  • Vitamins
  • Calcitriol
  • Cinacalcet